RealTime Dynamix: Psoriatic Arthritis EU (annual)

The EU Psoriatic Arthritis (PsA) market has been experiencing large-scale change as rheumatologists continue adoption of alternate MOA biologics. Uptake of Novartis’ Cosentyx, BMS’ Orencia, and Eli Lilly’s Taltz will challenge the leading TNF-inhibitors, while a pipeline ripe with line-extensions and new agents is due to bring further disruption.

The RealTime Dynamix™: Psoriatic Arthritis (EU) report series provides a detailed and timely look at current and future trends in the PsA market, and the effects of the future shifting landscape. The annual releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated annually. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the PsA market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.

The report is based on an online survey of ~250 rheumatologists practicing in the EU5. Rheumatologists meet screening criteria including time in practice, percent of professional time spent in clinical practice (vs. teaching or research), minimum number of PsA patients, and minimum number of PsA patients on biologic agents. Surveys are programmed in the local language.

Join Our Newsletter

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About Cookies page.OKREAD MORE